Neuroendocrine Tumors: all 682 studies
Page 6 of 7. Open to participants first (163), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to UseTerminatedNCT03145857Phase 1/2
- DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine TumorCompletedNCT03143946Not applicable
- Biomarker Study in Pancreatic Neuroendocrine TumoursStatus unknownNCT03130205
- Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine TumorsCompletedNCT03112694
- Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NETStatus unknownNCT03083210Phase 4
- TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03079440Phase 2
- Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)Status unknownNCT03053999
- Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine TumorsActive, not recruitingNCT03044977Early Phase 1
- Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)Active, not recruitingNCT03043508
- 18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyCompletedNCT03042416Phase 3
- Everolimus TDM to Predict Long Term ToxicityStatus unknownNCT03033186
- Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic IncidentalomaActive, not recruitingNCT03022188
- Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)CompletedNCT03017690
- Fosbretabulin With Everolimus in Neuroendocrine Tumors With ProgressionTerminatedNCT03014297Phase 1
- Surgical Intervention and the NETestCompletedNCT03012789Not applicable
- 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine TumorsTerminatedNCT03001349Early Phase 1
- Circulating Tumor Cells and Tumor DNA in HCC and NETCompletedNCT02973204
- Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine TumorsCompletedNCT02948946
- Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETsTerminatedNCT02943733Phase 1
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersCompletedNCT02923934Phase 2
- Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic TumorsWithdrawnNCT02882503Not applicable
- Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine TumoursCompletedNCT02853422
- Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST CriteriaCompletedNCT02841865
- SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine TumorsCompletedNCT02840149Phase 3
- Identification of Biomarker Profiles GEP-NEN PatientsStatus unknownNCT02838862
- Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine TumorsCompletedNCT02838342Phase 2
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- The MetNET-2 TrialStatus unknownNCT02823691Early Phase 1
- Dual SSTR2 and Integrin αvβ3 Targeting PET/CT ImagingStatus unknownNCT02817945Early Phase 1
- The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine TumorsCompletedNCT02815969
- Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin ReceptorsCompletedNCT02810600
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2
- A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine TumoursTerminatedNCT02788578
- Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine TumoursCompletedNCT02788565
- Interest of Whole-body MRI Correlated to Spreading Sequences for Staging Neuroendocrine TumorsStatus unknownNCT02786303Not applicable
- Pasireotide Treatment for Neuroendocrine TumorWithdrawnNCT02779257Phase 4
- Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine TumorsStatus unknownNCT02759718Phase 4
- Personalized PRRT of Neuroendocrine TumorsActive, not recruitingNCT02754297Phase 2
- Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and EfficacyActive, not recruitingNCT02749331Phase 1/2
- Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine TumorsCompletedNCT02743741Not applicable
- Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine TumorsCompletedNCT02736500Phase 1/2
- 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsTerminatedNCT02736448Phase 2
- Community-based Neuroendocrine Tumor (NET) Research StudyCompletedNCT02730104
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the LiverCompletedNCT02724540Phase 2
- Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to SunitinibCompletedNCT02713763Phase 2
- Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO TreatmentStatus unknownNCT02705651Phase 3
- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA TxApproved for marketingNCT02705313
- A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the LiverStatus unknownNCT02693067Phase 1
- Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine TumorsCompletedNCT02691078Phase 2
- Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN ProjectCompletedNCT02685553Phase 1
- Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective AnalysisCompletedNCT02646644
- Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsCompletedNCT02630654
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
- Nonfunctional Pancreatic NET and PET ImagingStatus unknownNCT02621541Phase 4
- Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsCompletedNCT02611024Phase 1/2
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsCompletedNCT02589821Phase 3
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsCompletedNCT02588170Phase 3
- Prospective Comprehensive Molecular Profiling In Neuroendocrine TumorsCompletedNCT02586844
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
- Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)CompletedNCT02539433Not applicable
- 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'CompletedNCT02507908
- Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsTerminatedNCT02489604Phase 2
- Optimal Feeding for NET PatientsCompletedNCT02481804Not applicable
- Web-based Tailored Information and Support for Patients With a Neuroendocrine TumorCompletedNCT02472678Not applicable
- Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine TumorTerminatedNCT02465112Phase 3
- Study of rSIFN-co for Patients With Advanced Solid TumorsTerminatedNCT02464007Phase 1
- Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine TumorsStatus unknownNCT02455596Phase 2
- 18F-FDOPA PET in Neuroendocrine TumoursNo longer availableNCT02431715
- Gallium-68 DOTATOC for Management of Neuroendocrine TumorsNo longer availableNCT02375464
- 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)TerminatedNCT02359500Phase 1
- Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours StudyCompletedNCT02358356Phase 2
- 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access TrialNo longer availableNCT02358018
- Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1CompletedNCT02355535Phase 1
- 18F-MFBG Imaging for Evaluation of Neuroendocrine MalignanciesCompletedNCT02348749Phase 1/2
- A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With EverolimusCompletedNCT02305810Phase 2
- A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine TumorsStatus unknownNCT02279758Phase 2
- Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 StudyCompletedNCT02279602Phase 2
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bCompletedNCT02279433Phase 1
- Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine TumorsCompletedNCT02267967Phase 1
- A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.Status unknownNCT02246322Not applicable
- 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)No longer availableNCT02174679
- Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine TumorsCompletedNCT02150408Not applicable
- Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility StudyCompletedNCT02147106
- PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical EvaluationCompletedNCT02134639Phase 1
- Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic NeoplasmsCompletedNCT02125929Not applicable
- Efficacy of 177-Lu-DOTA 0, Tyr 3 OctreotateCompletedNCT02125474Not applicable
- Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II StudyCompletedNCT02113800Phase 2
- Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaTerminatedNCT02110563Phase 1
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsWithdrawnNCT02108782Phase 2
- Gastroenteral-Pancreatic Neuroendocrine Tumors in TaiwanCompletedNCT02102893
- Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine TumorsStatus unknownNCT02092714
- 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.Active, not recruitingNCT02088645Phase 1
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine TumorsTerminatedNCT02078843Phase 1/2
- Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
- Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy StudyCompletedNCT02067988Phase 2
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine TumorsCompletedNCT02063958Phase 1
- 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine TumorsStatus unknownNCT02038738Phase 1/2
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2
- 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive TumorsNo longer availableNCT01980732
- Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and ParagangliomaWithdrawnNCT01941849Phase 1